Smarter prophylaxis: How RHD testing protects patients and resources
The supply of anti-D immunoglobulin, a prophylactic cornerstone of maternal care, has come under...
In this case study, Dr. Papasavva describes her laboratory’s journey from traditional thalassemia testing to state-of-the-art NGS technology and what a difference this has made in their daily work.
Infographic
This infographic details a modern approach to targeted, ethical, and efficient RhD management.
Devyser RHD is a unique non-invasive test solution that determines fetal RHD status from maternal plasma from week 10 of pregnancy. The single-exon kit delivers a turnaround time of less than five hours and a hands-on time of less than 60 minutes. Devyser RHD has a high clinical relevance that is proven from routine usage over the course of years.
The supply of anti-D immunoglobulin, a prophylactic cornerstone of maternal care, has come under...
Read More
Over the past decade, there has been a wealth of research investigating the ideal approach to RHD...
Read More
Devyser is today announcing that its product for non-invasive fetal RHD testing has been granted...
Read More
Devyser is today announcing that the company’s clinical testing laboratory in Roswell in Atlanta,...
Read More